MX2022000103A - Compuestos para el tratamiento de trastornos oculares. - Google Patents

Compuestos para el tratamiento de trastornos oculares.

Info

Publication number
MX2022000103A
MX2022000103A MX2022000103A MX2022000103A MX2022000103A MX 2022000103 A MX2022000103 A MX 2022000103A MX 2022000103 A MX2022000103 A MX 2022000103A MX 2022000103 A MX2022000103 A MX 2022000103A MX 2022000103 A MX2022000103 A MX 2022000103A
Authority
MX
Mexico
Prior art keywords
compounds
treatment
eye disorders
angiogenesis
solvates
Prior art date
Application number
MX2022000103A
Other languages
English (en)
Inventor
Srinivasaraghavan Kannan
Hong Hwa Lim
Chandra Shekhar Verma
Uttam Surana
Original Assignee
Sinopsee Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinopsee Therapeutics filed Critical Sinopsee Therapeutics
Publication of MX2022000103A publication Critical patent/MX2022000103A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de la Fórmula I como se definen en la presente descripción, o sales farmacéuticamente aceptables, solvatos o derivados de estas, son inhibidores potentes de la angiogénesis y, en consecuencia, son útiles en el tratamiento y prevención de diversos trastornos relacionados con la angiogénesis, tales como el cáncer.
MX2022000103A 2019-06-25 2020-06-25 Compuestos para el tratamiento de trastornos oculares. MX2022000103A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201905890P 2019-06-25
PCT/SG2020/050363 WO2020263187A1 (en) 2019-06-25 2020-06-25 Compounds for treatment of eye disorders

Publications (1)

Publication Number Publication Date
MX2022000103A true MX2022000103A (es) 2022-04-27

Family

ID=74062096

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022000103A MX2022000103A (es) 2019-06-25 2020-06-25 Compuestos para el tratamiento de trastornos oculares.
MX2022000099A MX2022000099A (es) 2019-06-25 2020-06-25 Compuestos para el tratamiento del cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000099A MX2022000099A (es) 2019-06-25 2020-06-25 Compuestos para el tratamiento del cancer.

Country Status (11)

Country Link
US (2) US20220242863A1 (es)
EP (2) EP3990458A1 (es)
JP (2) JP2022542645A (es)
KR (1) KR20220054286A (es)
CN (2) CN114450285B (es)
AU (2) AU2020307293A1 (es)
BR (1) BR112021026366A2 (es)
CA (2) CA3144226A1 (es)
IL (2) IL289201A (es)
MX (2) MX2022000103A (es)
WO (2) WO2020263186A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113354576B (zh) * 2021-06-28 2022-08-12 黑龙江立科新材料有限公司 邻位烷氧基取代的吡啶类化合物的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
CA2572331A1 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
DOP2006000051A (es) * 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
GB0507575D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
KR100787131B1 (ko) * 2006-07-04 2007-12-21 한국생명공학연구원 Ｈｉｆ―１ 활성을 저해하는 화합물, 이의 제조방법 및이를 유효성분으로 함유하는 약학적 조성물
WO2008046802A1 (en) * 2006-10-16 2008-04-24 Novartis Ag Phenylacetamides useful as protein kinase inhibitors
WO2008112695A2 (en) * 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
WO2014055999A2 (en) * 2012-10-05 2014-04-10 Kadmon Corporation, Llc Treatment of ocular disorders
GB2508652A (en) * 2012-12-07 2014-06-11 Agency Science Tech & Res Heterocyclic piperazine derivatives
RU2016111675A (ru) * 2013-08-30 2017-10-04 Эмбит Байосайенсиз Корпорейшн Соединения биарилацетамида и способы их применения
WO2015043492A1 (en) * 2013-09-26 2015-04-02 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and uses thereof in medicine
CN105294680A (zh) * 2014-06-25 2016-02-03 中国药科大学 Vegfr-2不可逆抑制剂及其用途
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
CN104876912B (zh) * 2015-04-08 2017-07-21 苏州云轩医药科技有限公司 Wnt信号通路抑制剂及其应用
KR102128018B1 (ko) * 2017-05-12 2020-06-30 한국화학연구원 피라졸로 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암, 자가면역질환 및 뇌질환의 예방 또는 치료용 약학적 조성물
WO2019132782A1 (en) * 2017-12-29 2019-07-04 Agency For Science, Technology And Research Compounds for treating eye diseases and methods thereof

Also Published As

Publication number Publication date
WO2020263186A1 (en) 2020-12-30
JP2022543343A (ja) 2022-10-12
CN114450285B (zh) 2024-04-09
CA3144228A1 (en) 2020-12-30
CN114450285A (zh) 2022-05-06
AU2020301057A1 (en) 2022-01-27
EP3990457A1 (en) 2022-05-04
US20220242863A1 (en) 2022-08-04
JP2022542645A (ja) 2022-10-06
CA3144226A1 (en) 2020-12-30
IL289201A (en) 2022-02-01
AU2020307293A1 (en) 2022-01-27
KR20220054286A (ko) 2022-05-02
EP3990458A1 (en) 2022-05-04
EP3990457A4 (en) 2023-09-13
IL289221A (en) 2022-02-01
BR112021026366A2 (pt) 2022-03-03
WO2020263187A1 (en) 2020-12-30
CN114466847A (zh) 2022-05-10
MX2022000099A (es) 2022-04-27
US20220315587A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
MX2020013014A (es) N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
SA519401541B1 (ar) [1، 5-a] مركبات بيرازولو كيناز ret بيريدين بها استبدال كمثبطات
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
PH12020551464A1 (en) Cd73 inhibitors
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
MX2023001876A (es) Derivados de rapamicina.
MX2023010882A (es) Compuestos y composiciones para el tratamiento de trastornos hematológicos.
TN2016000501A1 (en) Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors.
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
MX2022005298A (es) Compuestos intermediarios de sintesis de inhibidores de a2a.
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
CR20220029A (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
MX2021007247A (es) Derivados de rapamicina.
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX2022000103A (es) Compuestos para el tratamiento de trastornos oculares.